Comparison of metabolic parameters during treatment for schizophrenia with olanzapine intramuscular long-acting injection versus olanzapine oral formulation

被引：0
|
作者：
Gulliver, A. [1 ]
McDonnell, D. P. [1 ]
Kryzhanovskaya, L. A. [1 ]
Zhao, F. [1 ]
Detke, H. C. [1 ]
Feldman, P. D. [1 ]
机构：
[1] Eli Lilly & Co, Lilly Res Labs, Indianapolis, IN 46285 USA
来源：
INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY | 2008年 / 11卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
引用
收藏
页码：152 / 152
页数：1
相关论文
共 50 条
  • [41] IMPROVEMENT IN PATIENT SYMPTOMS AND FUNCTIONING DURING LONG-TERM TREATMENT WITH OLANZAPINE LONG-ACTING INJECTION (OLAI)
    Peuskens, J.
    Porsdal, V.
    Pecenak, J.
    Handest, P.
    D'yachkova, Y.
    Brousil, R.
    Casillas, M.
    Deberdt, W.
    EUROPEAN PSYCHIATRY, 2011, 26
  • [42] Patient and Health Care Provider Perspectives on Long Acting Injectable Antipsychotics in Schizophrenia and the Introduction of Olanzapine Long-Acting Injection
    Wehring, Heidi J.
    Thedford, Sheryl
    Koola, Maju
    Kelly, Deanna L.
    JOURNAL OF CENTRAL NERVOUS SYSTEM DISEASE, 2011, 3 : 107 - 123
  • [43] Switching to olanzapine long-acting injection from either oral olanzapine or any other antipsychotic: comparative post hoc analyses
    Ciudad, Antonio
    Anand, Ernie
    Berggren, Lovisa
    Casillas, Marta
    Schacht, Alexander
    Perrin, Elena
    NEUROPSYCHIATRIC DISEASE AND TREATMENT, 2013, 9 : 1737 - 1750
  • [44] Effects of olanzapine long-acting injection on levels of functioning among acutely ill patients with schizophrenia
    Witte, Michael M.
    Case, Michael G.
    Schuh, Kory J.
    Ascher-Svanum, Haya
    CURRENT MEDICAL RESEARCH AND OPINION, 2012, 28 (03) : 315 - 323
  • [45] EARLY RESPONSE PREDICTS SUBSEQUENT RESPONSE TO OLANZAPINE LONG-ACTING INJECTIONS IN THE TREATMENT OF SCHIZOPHRENIA
    Ascher-Svanum, H.
    Zhao, F.
    Nyhuis, A.
    Lawson, A. H.
    Stauffer, V. L.
    Montgomery, W.
    Witte, M.
    Detke, H.
    McDonnell, D. P.
    VALUE IN HEALTH, 2010, 13 (07) : A553 - A553
  • [46] Comparison of long-acting antipsychotic injection and oral antipsychotics in schizophrenia
    Olivares, Jose M.
    Pinal, Beatriz
    Cinos, Carmen
    NEUROPSYCHIATRY, 2011, 1 (03) : 275 - 289
  • [47] Injection-related adverse events observed with olanzapine long-acting injection
    Gulliver, A.
    McDonnell, D. P.
    Sorsaburu, S.
    Brunner, E.
    Detke, H. C.
    Andersen, S. W.
    Bergstrom, R. F.
    Mitchell, M.
    Ogle, K.
    Stickelmeyer, M. P.
    Corya, S. A.
    INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY, 2008, 11 : 152 - 152
  • [48] Update: Post-injection syndrome observed with olanzapine long-acting injection
    Detke, H.
    Mcdonnell, D.
    Brunner, E.
    Watson, S.
    Kothare, P.
    Treuer, T.
    INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY, 2010, 13 : 244 - 244
  • [49] "Long-acting" olanzapine in maintenance therapy of schizophrenia: A study with plasma levels
    Mauri, Massimo C.
    Maffini, Michele
    Di Pace, Chiara
    Reggiori, Alessandra
    Paletta, Silvia
    Moliterno, Donatella
    Rovera, Chiara
    Altamura, Carlo A.
    INTERNATIONAL JOURNAL OF PSYCHIATRY IN CLINICAL PRACTICE, 2015, 19 (02) : 99 - 105
  • [50] OLANZAPINE "LONG-ACTING" IN MAINTENANCE THERAPY OF SCHIZOPHRENIA: A STUDY WITH PLASMA LEVELS
    Altamura, A. C.
    Rovera, Chiara
    Di Pace, C.
    Paletta, S.
    De Gaspari, I. F.
    MAuri, M. C.
    SCHIZOPHRENIA BULLETIN, 2015, 41 : S299 - S300
12345